What is the role of ranibizumab in the treatment of central retinal vein occlusion (CRVO)?

Updated: Apr 18, 2019
  • Author: Lakshmana M Kooragayala, MD; Chief Editor: Douglas R Lazzaro, MD, FAAO, FACS  more...
  • Print

Intravitreal injection of ranibizumab

Ranibizumab (Lucentis, Genentech, Inc.) is a humanized, affinity-matured VEGF antibody fragment that binds to and neutralizes all isoforms of VEGF.

The role of ranibizumab in the management of CRVO was reported in multiple studies. In the CRUISE and HORIZON studies, intravitreal injection of ranibizumab improved visual acuity and macular edema following CRVO, with low rates of ocular and nonocular safety events. Results suggest that, during the second year of ranibizumab treatment, follow-up and injections should be individualized. On average, patients with CRVO may require follow-up more frequent than every 3 months.

The CRYSTAL study was a 24-month phase-3b, open-label, single-arm, multicenter study conducted in a broad patient population with visual impairment resulting from macular edema secondary to CRVO, including those with macular ischemia or greater disease duration. An individualized dosing regimen of ranibizumab 0.5 mg driven by stabilization criteria for up to 12 months resulted in significant best-corrected visual acuity gain in a broad population of patients with macular edema secondary to CRVO, including those with macular ischemia at baseline. The safety findings were consistent with those reported in previous ranibizumab studies in patients with CRVO. [31, 32, 33, 34, 35, 36]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!